NASDAQ:ACST Acasti Pharma (ACST) Stock Price, News & Analysis $2.76 -0.07 (-2.47%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.69▼$2.8750-Day Range$2.60▼$3.3052-Week Range$1.72▼$3.59Volume10,803 shsAverage Volume20,536 shsMarket Capitalization$25.94 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Acasti Pharma alerts: Email Address Acasti Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside117.4% Upside$6.00 Price TargetShort InterestHealthy0.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.14) to ($0.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 starsMedical Sector516th out of 936 stocksPharmaceutical Preparations Industry235th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAcasti Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcasti Pharma has received no research coverage in the past 90 days.Read more about Acasti Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.11% of the float of Acasti Pharma has been sold short.Short Interest Ratio / Days to CoverAcasti Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acasti Pharma has recently increased by 281.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcasti Pharma does not currently pay a dividend.Dividend GrowthAcasti Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACST. Previous Next 2.4 News and Social Media Coverage News SentimentAcasti Pharma has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Acasti Pharma this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Acasti Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acasti Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders13.51% of the stock of Acasti Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.08% of the stock of Acasti Pharma is held by institutions.Read more about Acasti Pharma's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Acasti Pharma are expected to grow in the coming year, from ($1.14) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acasti Pharma is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acasti Pharma is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcasti Pharma has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Acasti Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Acasti Pharma Stock (NASDAQ:ACST)Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Read More ACST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACST Stock News HeadlinesJuly 27 at 3:10 AM | americanbankingnews.comAcasti Pharma Inc. (NASDAQ:ACST) Sees Significant Increase in Short InterestJuly 24 at 5:15 PM | seekingalpha.comACST Acasti Pharma Inc.July 27, 2024 | The Oxford Club (Ad)Alex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.June 27, 2024 | globenewswire.comAcasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety TrialJune 21, 2024 | investorplace.comACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024June 21, 2024 | globenewswire.comAcasti Announces Year-End 2024 Financial Results, Provides Business UpdateJune 18, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024May 28, 2024 | globenewswire.comAcasti Pharma to Attend BIO International Convention 2024July 27, 2024 | The Oxford Club (Ad)Alex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.May 23, 2024 | investorplace.comThe Next Novavax? 3 Biopharma Stocks to Buy Before They BoomMay 21, 2024 | finance.yahoo.comInsider Stock Buying Reaches US$2.50m On Acasti PharmaMay 5, 2024 | fool.comAcasti Pharma (NASDAQ: ACST)December 14, 2023 | morningstar.comAcasti Pharma Inc Class ADecember 13, 2023 | finance.yahoo.comAcasti to Participate in Upcoming San Francisco Investor Conferences in January 2024November 13, 2023 | finance.yahoo.comAcasti Announces Second Quarter 2024 Financial Results and Business HighlightsOctober 18, 2023 | markets.businessinsider.comOptimistic Outlook for Acasti Pharma’s GTX-104: Assessing Buy Rating and Potential Impact on Aneurysmal Subarachnoid Hemorrhage TreatmentOctober 4, 2023 | finance.yahoo.comAcasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)September 27, 2023 | seekingalpha.comAcasti announces $7.5M private placement equity fundingSee More Headlines Receive ACST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/21/2024Today7/27/2024Next Earnings (Estimated)8/09/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACST CUSIPN/A CIK1444192 Webwww.acastipharma.com Phone45-0686-4555Fax45-0687-2272Employees32Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+117.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-13.24% Return on Assets-11.33% Debt Debt-to-Equity RatioN/A Current Ratio14.26 Quick Ratio14.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.57 per share Price / Book0.42Miscellaneous Outstanding Shares9,400,000Free Float8,129,000Market Cap$25.94 million OptionableNot Optionable Beta1.55 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Prashant Kohli (Age 52)CEO & Director Comp: $358.41kMr. Robert J. DelAversano CPA (Age 52)Principal Financial & Accounting Officer Dr. R. Loch MacDonald M.D. (Age 62)Ph.D., Member of Scientific Advisory Board & Chief Medical Officer Mr. Amresh Kumar Ph.D. (Age 44)VP of Program Management Ms. Carrie D'Andrea (Age 52)VP of Clinical Operations Key CompetitorsOramed PharmaceuticalsNASDAQ:ORMPAclaris TherapeuticsNASDAQ:ACRSSagimet BiosciencesNASDAQ:SGMTDBV TechnologiesNASDAQ:DBVTAtlantic Coastal Acquisition Corp. IINASDAQ:ACABView All CompetitorsInsidersVimal KavuruBought 676,371 shares on 9/25/2023Total: $1.25 M ($1.85/share)Donald OldsBought 381 shares on 8/31/2023Total: $781.05 ($2.05/share)View All Insider Transactions ACST Stock Analysis - Frequently Asked Questions How have ACST shares performed this year? Acasti Pharma's stock was trading at $2.89 at the start of the year. Since then, ACST shares have decreased by 4.5% and is now trading at $2.76. View the best growth stocks for 2024 here. How were Acasti Pharma's earnings last quarter? Acasti Pharma Inc. (NASDAQ:ACST) released its quarterly earnings data on Friday, June, 21st. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.30. When did Acasti Pharma's stock split? Acasti Pharma's stock reverse split on Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. How do I buy shares of Acasti Pharma? Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA) and Heat Biologics (HTBX). This page (NASDAQ:ACST) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acasti Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.